NO20072665L - Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser - Google Patents

Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser

Info

Publication number: NO20072665L
Authority: NO; Norway
Prior art keywords: neurological disorders; treatment; rapamycin derivatives; compounds; rapamycin
Prior art date: 2004-12-20

Application number

NO20072665A

Other languages

English (en)

Norwegian (no)

Inventor

Kevin Pong

Edmund Idris Graziani

Jerauld Skotnicki

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-20

Filing date

2007-05-25

Publication date

2007-09-07

2007-05-25 Application filed by Wyeth Corp filed Critical Wyeth Corp

2007-09-07 Publication of NO20072665L publication Critical patent/NO20072665L/no

Links

208000012902 Nervous system disease Diseases 0.000 title abstract 3
208000025966 Neurological disease Diseases 0.000 title abstract 2
QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 2
206010019196 Head injury Diseases 0.000 abstract 1
230000000626 neurodegenerative effect Effects 0.000 abstract 1
230000000324 neuroprotective effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Addiction (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Emergency Medicine (AREA)
Pregnancy & Childbirth (AREA)
Vascular Medicine (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)

NO20072665A 2004-12-20 2007-05-25 Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser NO20072665L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63800404P	2004-12-20	2004-12-20
PCT/US2005/045331 WO2006068905A2 (fr)	2004-12-20	2005-12-15	Derives de paramycine et leurs utilisations dans le traitement de troubles neurologiques

Publications (1)

Publication Number	Publication Date
NO20072665L true NO20072665L (no)	2007-09-07

Family

ID=36602218

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072665A NO20072665L (no)	2004-12-20	2007-05-25	Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser

Country Status (16)

Country	Link
US (3)	US7273874B2 (fr)
EP (1)	EP1828203A2 (fr)
JP (1)	JP2008524232A (fr)
KR (1)	KR20070090931A (fr)
CN (1)	CN101084226A (fr)
AU (1)	AU2005319427B2 (fr)
BR (1)	BRPI0519593A2 (fr)
CA (1)	CA2590254A1 (fr)
CR (1)	CR9149A (fr)
IL (1)	IL183772A0 (fr)
MX (1)	MX2007007409A (fr)
NI (1)	NI200700156A (fr)
NO (1)	NO20072665L (fr)
RU (1)	RU2007119585A (fr)
WO (1)	WO2006068905A2 (fr)
ZA (1)	ZA200705123B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004011000A1 (fr)	2002-07-30	2004-02-05	Wyeth	Formulations parenterales contenant un hydroxyester de rapamycine
SG150518A1 (en) *	2004-03-02	2009-03-30	Wyeth Corp	Macrolides and methods for producing same
CA2567043A1 (fr) *	2004-06-03	2005-12-22	Wyeth	Groupe de genes biosynthetiques utilise dans la production d'un polyketide complexe
GT200500368A (es) *	2004-12-20	2006-07-13		Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CN101084226A (zh) *	2004-12-20	2007-12-05	惠氏公司	雷帕霉素衍生物及其治疗神经紊乱的用途
EP1859274A2 (fr) *	2005-03-07	2007-11-28	Novartis AG	Genes associes a des etats neurodegeneratifs
WO2007067560A2 (fr) *	2005-12-07	2007-06-14	Wyeth	Procede evolutif pour la preparation d'un 42-ester de rapamycine a partir d'un borate de 42-ester de rapamycine
AU2006322030A1 (en) *	2005-12-07	2007-06-14	Wyeth	Methods for preparing crystalline rapamycin and for measuring crystallinity of rapamycin compounds using differential scanning calorimetry
BRPI0619493A2 (pt) *	2005-12-07	2016-09-06	Wyeth Corp	forma cristalina purificada de cci-779, processo para a purificação de cc-779, produto, método para monitorar a cristalização de cci-779, kit, composição farmacêutica, método para o tratamento de câncer, e, uso de um cci-779 purificado
AU2007223962A1 (en)	2006-03-07	2007-09-13	Wyeth	Meridamycin analogues for the treatment of neurodegenerative disorders
TW200824713A (en) *	2006-10-18	2008-06-16	Wyeth Corp	Processes for the synthesis of individual isomers of mono-PEG CCI-779
US8414909B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414526B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9700704B2 (en)	2006-11-20	2017-07-11	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8425459B2 (en)	2006-11-20	2013-04-23	Lutonix, Inc.	Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US8998846B2 (en)	2006-11-20	2015-04-07	Lutonix, Inc.	Drug releasing coatings for balloon catheters
US8414525B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US8414910B2 (en)	2006-11-20	2013-04-09	Lutonix, Inc.	Drug releasing coatings for medical devices
US20080276935A1 (en)	2006-11-20	2008-11-13	Lixiao Wang	Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US9737640B2 (en)	2006-11-20	2017-08-22	Lutonix, Inc.	Drug releasing coatings for medical devices
EP2077853A1 (fr) *	2007-01-29	2009-07-15	Wyeth	Ligands d'immunophilines et procedes pour moduler l'activite des immunophilines et des canaux calciques
JP2008305262A (ja) *	2007-06-08	2008-12-18	Konica Minolta Business Technologies Inc	サーバ及びシンクライアント環境でのプリンタ紹介方法
RU2499599C2 (ru)	2007-09-28	2013-11-27	Интрексон Корпорейшн	Конструкции терапевтического переключения генов и биореакторы для экспрессии биотерапевтических молекул и их применение
WO2009105510A1 (fr) *	2008-02-19	2009-08-27	Wyeth	Procédés d’utilisation d’analogues de la rapamycine pour le traitement de troubles neurologiques
WO2010024898A2 (fr)	2008-08-29	2010-03-04	Lutonix, Inc.	Procédés et appareils pour poser un revêtement sur des cathéters à ballonnet
CN104042612A (zh)	2008-11-11	2014-09-17	得克萨斯大学体系董事会	哺乳动物雷帕霉素靶蛋白的抑制
DE102008060549A1 (de)	2008-12-04	2010-06-10	MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V.	Wirkstoff-Peptid-Konstrukt zur extrazellulären Anreicherung
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
CN103038343A (zh)	2010-03-23	2013-04-10	英特瑞克斯顿股份有限公司	条件表达治疗蛋白的载体，包含所述载体的宿主细胞，及其应用
ES2372077B2 (es) *	2010-06-24	2012-05-18	Universidad De Sevilla	Uso de la rapamicina para el tratamiento de los déficits cognitivos asociados al s�?ndrome de down.
WO2012122025A2 (fr)	2011-03-04	2012-09-13	Intrexon Corporation	Vecteurs exprimant une protéine de façon conditionnelle
CN102274219A (zh) *	2011-06-27	2011-12-14	苏州大学附属第一医院	雷帕霉素在治疗蛛网膜下腔出血早期脑损伤的应用
CA2926747A1 (fr)	2012-10-12	2014-04-17	Arlan RICHARDSON	Utilisation d'inhibiteurs mtor pour traiter le deficit cognitif vasculaire
US9121859B2 (en) *	2012-12-04	2015-09-01	Siemens Healthcare Diagnostics Inc.	Compounds and methods for determination of FKBP-binding immunosuppressant drugs
DK2968281T3 (da)	2013-03-13	2020-11-02	Univ Texas	Mtor-hæmmere til forebyggelse af vækst af tarmpolyp
DK3089737T3 (da)	2013-12-31	2021-12-13	Rapamycin Holdings Llc	Orale rapamycin-nanopartikelpræparater og anvendelse.
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
UY37343A (es)	2016-07-25	2018-02-28	Intrexon Corp	Control del fenotipo en plantas
US11116852B2 (en)	2016-11-09	2021-09-14	Precigen, Inc.	Frataxin expression constructs
EP3624863B1 (fr)	2017-05-15	2021-04-14	C.R. Bard, Inc.	Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
WO2019157382A1 (fr) *	2018-02-09	2019-08-15	Mount Tam Therapeutics, Inc.	Analogue de la rapamycine pour la prévention et/ou le traitement d'états neurodégénératifs
WO2019157374A1 (fr) *	2018-02-09	2019-08-15	Mount Tam Therapeutics, Inc.	Analogue de la rapamycine pour la prévention et/ou le traitement d'états neurodégénératifs
WO2020101675A1 (fr)	2018-11-14	2020-05-22	Lutonix, Inc.	Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée
WO2020209828A1 (fr)	2019-04-08	2020-10-15	Bard Peripheral Vascular, Inc.	Dispositif médical portant un revêtement d'élution de médicament sur une surface modifiée de dispositif
WO2022033529A1 (fr) *	2020-08-12	2022-02-17	洪明奇	Utilisation d'un antagoniste de sema3d dans la prévention ou le traitement de maladies neurodégénératives et prolongeant la durée de vie
WO2022272154A2 (fr) *	2021-06-25	2022-12-29	Apertor Pharmaceuticals, Inc.	Composés à petites molécules

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1445742A1 (de)	1963-11-06	1968-12-19	Bayer Ag	Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
DE1545824A1 (de)	1965-06-21	1969-12-11	Bayer Ag	Verfahren zur Herstellung von 2-Sulfonamido- bzw. 2-Sulfonhydrazido-Benzoxazinonen
CA930734A (en)	1969-08-11	1973-07-24	Bickel Hans	Antibiotically active rifamycin compounds and processes for their manufacture
US3686238A (en)	1970-01-19	1972-08-22	Syntex Corp	Glycerol esterified with 2-naphthyl-acetic acids and fatty acids
US3900465A (en)	1973-04-05	1975-08-19	Lepetit Spa	3-formylrifamycin azines
US3905981A (en)	1973-10-12	1975-09-16	Research Corp	N-dealkylation of tertiary amines
US4127720A (en)	1977-09-21	1978-11-28	Bristol-Myers Company	Pyrimido[2,1-a]isoquinoline derivatives having antiallergy activity
JPH0262875A (ja)	1988-05-23	1990-03-02	Wakunaga Pharmaceut Co Ltd	新規イソインドリン誘導体
JPH05507915A (ja)	1990-06-11	1993-11-11	藤沢薬品工業株式会社	特発性血小板減少性紫斑病およびバセドウ病治療薬製造のためのｆｋ５０６等のマクロライド化合物の用途
DE4021404A1 (de)	1990-07-05	1992-01-09	Sandoz Ag	Heteroatome enthaltende trycyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung
US5023262A (en)	1990-08-14	1991-06-11	American Home Products Corporation	Hydrogenated rapamycin derivatives
GB2249027A (en)	1990-10-23	1992-04-29	Fujisawa Pharmaceutical Co	Use of macrolide compounds for hepatic failure
WO1992013862A1 (fr)	1991-02-05	1992-08-20	Fujisawa Pharmaceutical Co., Ltd.	Composes de lactone
US5604294A (en)	1991-09-05	1997-02-18	Luly; Jay R.	Macrocyclic immunomodulators
CA2103454C (fr)	1991-09-05	2004-11-02	Jay R. Luly	Immunomodulateurs macrocycliques
ZA935112B (en)	1992-07-17	1994-02-08	Smithkline Beecham Corp	Rapamycin derivatives
ZA935111B (en)	1992-07-17	1994-02-04	Smithkline Beecham Corp	Rapamycin derivatives
JPH08509499A (ja)	1993-04-23	1996-10-08	アボツト・ラボラトリーズ	ラパマイシン結合体及び抗体
US7279561B1 (en)	1993-04-23	2007-10-09	Wyeth	Anti-rapamycin monoclonal antibodies
US5798355A (en)	1995-06-07	1998-08-25	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity
US5525610A (en)	1994-03-31	1996-06-11	American Home Products Corporation	42-Epi-rapamycin and pharmaceutical compositions thereof
US5696135A (en)	1995-06-07	1997-12-09	Gpi Nil Holdings, Inc.	Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
TW427904B (en)	1995-12-07	2001-04-01	American Home Prod	Neuroprotective agents
US5717092A (en)	1996-03-29	1998-02-10	Vertex Pharmaceuticals Inc.	Compounds with improved multi-drug resistance activity
US5780484A (en)	1996-11-13	1998-07-14	Vertex Pharmaceuticals Incorporated	Methods for stimulating neurite growth with piperidine compounds
US6187784B1 (en)	1998-06-03	2001-02-13	Gpi Nil Holdings, Inc.	Pipecolic acid derivative hair growth compositions and uses
WO1999062483A1 (fr)	1998-06-03	1999-12-09	Gpi Nil Holdings, Inc.	Compositions pour la croissance des cheveux a base de derives d'acide pipecolique et utilisation de ces compositions
US6376517B1 (en)	1998-08-14	2002-04-23	Gpi Nil Holdings, Inc.	Pipecolic acid derivatives for vision and memory disorders
US6015809A (en)	1998-08-17	2000-01-18	American Home Products Corporation	Photocyclized rapamycin
WO2000009510A1 (fr)	1998-08-17	2000-02-24	American Home Products Corporation	Rapamycines photocyclisees
WO2000034239A2 (fr)	1998-12-08	2000-06-15	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
EP1214326A1 (fr)	1999-09-09	2002-06-19	Merck & Co., Inc.	Inhibiteurs de prenyl-proteine transferase
US6569867B2 (en)	1999-10-01	2003-05-27	Kosan Biosciences, Inc.	Polyketide derivatives
AU2748701A (en)	1999-10-29	2001-06-06	Kosan Biosciences, Inc.	Rapamycin analogs
CA2407259A1 (fr)	2000-05-17	2001-11-22	Chaitan Khosla	Nouveaux derives polycetides
CN1545512A (zh)	2001-08-22	2004-11-10	惠氏公司	雷帕霉素二醛化合物
ATE305932T1 (de)	2001-08-22	2005-10-15	Wyeth Corp	Rapanycin29-enole
US7300942B2 (en)	2002-07-16	2007-11-27	Biotica Technology Limited	Production of polyketides and other natural products
CN101084226A (zh)	2004-12-20	2007-12-05	惠氏公司	雷帕霉素衍生物及其治疗神经紊乱的用途
GT200500368A (es)	2004-12-20	2006-07-13		Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
AU2007223962A1 (en)	2006-03-07	2007-09-13	Wyeth	Meridamycin analogues for the treatment of neurodegenerative disorders

2005
- 2005-12-15 CN CNA2005800437050A patent/CN101084226A/zh active Pending
- 2005-12-15 KR KR1020077013852A patent/KR20070090931A/ko not_active Withdrawn
- 2005-12-15 AU AU2005319427A patent/AU2005319427B2/en not_active Ceased
- 2005-12-15 CA CA002590254A patent/CA2590254A1/fr not_active Abandoned
- 2005-12-15 RU RU2007119585/04A patent/RU2007119585A/ru not_active Application Discontinuation
- 2005-12-15 BR BRPI0519593-4A patent/BRPI0519593A2/pt not_active IP Right Cessation
- 2005-12-15 WO PCT/US2005/045331 patent/WO2006068905A2/fr active Application Filing
- 2005-12-15 JP JP2007546876A patent/JP2008524232A/ja active Pending
- 2005-12-15 EP EP05854115A patent/EP1828203A2/fr not_active Withdrawn
- 2005-12-15 US US11/300,941 patent/US7273874B2/en not_active Expired - Fee Related
- 2005-12-15 MX MX2007007409A patent/MX2007007409A/es active IP Right Grant
2007
- 2007-05-24 CR CR9149A patent/CR9149A/es not_active Application Discontinuation
- 2007-05-25 NO NO20072665A patent/NO20072665L/no not_active Application Discontinuation
- 2007-06-07 IL IL183772A patent/IL183772A0/en unknown
- 2007-06-18 NI NI200700156A patent/NI200700156A/es unknown
- 2007-06-19 ZA ZA200705123A patent/ZA200705123B/xx unknown
- 2007-08-14 US US11/891,879 patent/US7476678B2/en not_active Expired - Fee Related
2008
- 2008-12-05 US US12/329,106 patent/US20090088448A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080027089A1 (en)	2008-01-31
NI200700156A (es)	2008-06-17
US20090088448A1 (en)	2009-04-02
EP1828203A2 (fr)	2007-09-05
WO2006068905A3 (fr)	2006-12-07
WO2006068905A2 (fr)	2006-06-29
US7273874B2 (en)	2007-09-25
CN101084226A (zh)	2007-12-05
KR20070090931A (ko)	2007-09-06
ZA200705123B (en)	2010-01-27
CR9149A (es)	2007-10-23
MX2007007409A (es)	2007-07-12
AU2005319427B2 (en)	2011-11-03
BRPI0519593A2 (pt)	2009-02-25
JP2008524232A (ja)	2008-07-10
IL183772A0 (en)	2007-09-20
AU2005319427A1 (en)	2006-06-29
US7476678B2 (en)	2009-01-13
RU2007119585A (ru)	2009-01-27
CA2590254A1 (fr)	2006-06-29
US20060135550A1 (en)	2006-06-22

Legal Events

Date	Code	Title	Description
2010-07-19	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20072665L (no)	2007-09-07	Rapamycinderivater og deres anvendelse i behandling av nevrologiske lidelser
EA200870093A1 (ru)	2009-02-27	Применение производных бензоконденсированного гетероциклического сульфамида для лечения ожирения
NO20072664L (no)	2007-06-25	Rapamycinanaloger og anvendelser derav for behandling av neurologiske, proliferative og inflamatoriske forstyrrelser
DK1543011T3 (da)	2006-08-07	Thienopyrrolyl- og furanopyrrolylforbindelser og deres anvendelse som histamin H4-receptorligander
EA200800081A1 (ru)	2008-06-30	Бензамидные производные (варианты), содержащая их фармацевтическая композиция (варианты), способ лечения заболеваний, связанных с модуляцией гидроксистероиддегидрогеназ на основе указанных производных(варианты)
NO20081315L (no)	2008-05-15	Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser
NO20064929L (no)	2006-12-20	Sulfonamid-tiazolpyrldinderivater som glukokinaseaktivatorer anvendelige i behandlingen av type 2 diabetes
TNSN07111A1 (en)	2008-06-02	Preparation and use of biphenyl-4-yl- carbonylamino acid derivatives for the treatment of obesity.
NO20080475L (no)	2008-04-15	Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
NO20074959L (no)	2007-10-02	Substituerte pyridinderivater
NO20082096L (no)	2008-05-29	Azaindol-2-karboksamidderivativer
NO20064325L (no)	2006-11-22	Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
NO20082136L (no)	2008-06-30	1,5-substituerte indol-2-yl-amidderivater
WO2008002956A3 (fr)	2008-07-03	Dérivés de thiazoline et d'oxazoline et leurs procédés d'utilisation
WO2007145835A3 (fr)	2008-03-06	Dérivés de benzamide et utilisations associées à ceux-ci
WO2008115999A8 (fr)	2008-12-24	Composés biaryle et bihétéroaryle utiles pour le traitement des troubles du fer
WO2006110187A3 (fr)	2007-04-26	Methodes et compositions pour le traitement de troubles anxieux
NO20083036L (no)	2008-09-05	Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av depresjon
DK1926729T3 (da)	2012-03-19	Benzothiazolcyclobutylaminderivater og deres anvendelse som histamin-3-receptorligander
NO20083058L (no)	2008-10-09	Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
BR0316723A (pt)	2005-10-18	Derivados de anilinopirazol úteis para o tratamento de diabetes
EA200600071A1 (ru)	2006-08-25	Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
NO20043952L (no)	2004-10-22	Benzofuran- og benzotiofenderivater som er nyttige ved behandling av hyperproliferative forstyrrelser
BRPI0506970A (pt)	2007-07-03	derivados de alfa-aminoamida úteis no tratamento de distúrbios do trato urinário inferior
WO2002079169A8 (fr)	2004-04-29	Composes de dihydropyrimidine cyano-substitues et leur utilisation pour traiter des maladies